Skip to main content
. 2017 Nov 8;6(2):197–211. doi: 10.1007/s40120-017-0084-6

Table 1.

Study schedule

Survey criteria Questionnaire form for 1 year (0–12 M) Questionnaire form for 2 years (12–24 M)
Patient background
Primary disease
Condition of administration
Discontinuation/dropout
Previous medication/treatment
Concomitant drug/treatment
Anti-JCV antibody 0, 6, 12 M 18, 24 M
Anti-natalizumab antibody
Anti-AQP4 antibody
Clinical course
Relapse
EDSSa 0, 3, 6, 9, 12 M 15, 18, 21, 24 M
Adverse event
Laboratory testing

M months, JCV John Cunningham virus, AQP4 aquaporin-4, EDSS expanded disability status scale

aSince EDSS was measured in a real-world clinical setting, the last evaluated score was used for analysis